IP Library Granted Patent US 11,446,249
Granted Patent B2
US 11,446,249 · App. 16/931,615 · Granted Sep 20, 2022

Viral vector stabilization

Inventors: Minna Hassinen (Kuopio, FI); Robert Shaw (Chinnor, GB); Nigel Parker (Chinnor, GB)
Assignee: Trizell Ltd.
A61K9/19A61K47/42C12N7/00C12N15/86C12N2710/10343
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,446,249
App. No.
16/931,615
Granted
Sep 20, 2022
Kind
B2
Abstract

Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.

Claims (8)

1. A method of preserving the infectivity of a recombinant adenovirus, comprising: mixing the recombinant adenovirus comprising a transgene and having infectivity with a surfactant to form an admixture; removing substantially all water from the admixture, and storing the admixture at or about 4° C. or room temperature for at least about one week, wherein after the storing step the adenovirus retains a higher level of infectivity relative to control, and wherein the surfactant has Structure I:

2. The method of claim 1 , wherein the adenovirus comprises attenuated adenovirus.

3. The method of claim 1 , wherein the transgene encodes interferon.

4. The method of claim 1 , wherein the transgene encodes interferon alpha-2b.

5. The method of claim 1 , wherein the admixture is stored at about 4° C. or room temperature for at least about three months.

6. The method of claim 1 , wherein the admixture is stored at about 4° C. or room temperature for at least about twelve months.

7. The method of claim 1 , wherein the adenovirus is replication-deficient and cannot replicate in normal human cells.

8. The method of claim 1 , wherein the adenovirus is a type 5 adenovirus.

Assignments (4)
CHANGE OF NAME Recorded Jul 10, 2025
From: TRIZELL LTD
To: FERRING VENTURES LTD
Reel/Frame 071655/0966 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2022
From: PHARMACEUTICAL PATENT ATTORNEYS, LLC
To: TRIZELL LTD., F/K/A FINVECTOR LTD. F/K/A ARK THERAPEUTICS LTD.
Reel/Frame 058826/0044 →
SECURITY INTEREST Recorded Nov 19, 2020
From: TRIZELL LTD.
To: PHARMACEUTICAL PATENT ATTORNEYS, LLC
Reel/Frame 054775/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: PARKER, NIGEL; SHAW, ROBERT; HASSINEN, MINNA
To: TRIZELL LTD.
Reel/Frame 053261/0777 →
Continuity (3)
Division 15781707
Provisional Application 62322452 · Apr 14, 2016
Related Publication 20200352862A1 · Nov 12, 2020